Literature DB >> 22859855

Treatment of idiopathic membranous nephropathy.

Meryl Waldman1, Howard A Austin.   

Abstract

Exciting progress recently has been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this disease. Here, we review important advances regarding the pathogenesis of membranous nephropathy. We will also review the current approach to treatment and its limitations and will highlight new therapies that are currently being explored for this disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone, with an emphasis on results of the most recent clinical trials.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22859855      PMCID： PMC3458460          DOI： 10.1681/ASN.2012010058

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


  87 in total

Review 1.  Basic and translational concepts of immune-mediated glomerular diseases.

Authors:  William G Couser
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

2.  Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy.

Authors:  A L Berg; P Nilsson-Ehle; M Arnadottir
Journal:  Kidney Int       Date:  1999-10       Impact factor: 10.612

Review 3.  Membranous nephropathy: recent travels and new roads ahead.

Authors:  Laurence H Beck; David J Salant
Journal:  Kidney Int       Date:  2010-02-24       Impact factor: 10.612

4.  Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment.

Authors:  Natalia Polanco; Elena Gutiérrez; Francisco Rivera; Ines Castellanos; José Baltar; Dolores Lorenzo; Manuel Praga
Journal:  Nephrol Dial Transplant       Date:  2011-05-30       Impact factor: 5.992

5.  Autoimmunity in membranous nephropathy targets aldose reductase and SOD2.

Authors:  Marco Prunotto; Maria Luisa Carnevali; Giovanni Candiano; Corrado Murtas; Maurizio Bruschi; Emilia Corradini; Antonella Trivelli; Alberto Magnasco; Andrea Petretto; Laura Santucci; Silvia Mattei; Rita Gatti; Francesco Scolari; Peter Kador; Landino Allegri; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2010-02-11       Impact factor: 10.121

6.  Current therapies for lupus nephritis in an ethnically heterogeneous cohort.

Authors:  Tania L Rivera; H Michael Belmont; Seema Malani; Melissa Latorre; Lauri Benton; Joseph Weisstuch; Laura Barisoni; Chung-E Tseng; Peter M Izmirly; Jill P Buyon; Anca D Askanase
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666

7.  A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.

Authors:  Vivekanand Jha; Anirban Ganguli; Tarun K Saha; Harbir S Kohli; Kamal Sud; Krishan L Gupta; Kusum Joshi; Vinay Sakhuja
Journal:  J Am Soc Nephrol       Date:  2007-05-09       Impact factor: 10.121

8.  Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.

Authors:  Peggy W G du Buf-Vereijken; Amanda J W Branten; Jack F M Wetzels
Journal:  Nephrol Dial Transplant       Date:  2004-02-19       Impact factor: 5.992

9.  Rituximab treatment of idiopathic membranous nephropathy.

Authors:  F C Fervenza; F G Cosio; S B Erickson; U Specks; A M Herzenberg; J J Dillon; N Leung; I M Cohen; D N Wochos; E Bergstralh; M Hladunewich; D C Cattran
Journal:  Kidney Int       Date:  2007-10-17       Impact factor: 10.612

10.  The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults.

Authors:  A M Davison; J S Cameron; D N Kerr; C S Ogg; R W Wilkinson
Journal:  Clin Nephrol       Date:  1984-08       Impact factor: 0.975
View more
  24 in total

1.  Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.

Authors:  Elion Hoxha; Ina Thiele; Gunther Zahner; Ulf Panzer; Sigrid Harendza; Rolf A K Stahl
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

2.  Efficacy and safety of long-course tacrolimus treatment for idiopathic membranous nephropathy.

Authors:  Jia Di; Qing Qian; Min Yang; Yaping Jiang; Hua Zhou; Min Li; Yun Zou
Journal:  Exp Ther Med       Date:  2018-05-23       Impact factor: 2.447

Review 3.  Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials.

Authors:  Yizhi Chen; Arrigo Schieppati; Guangyan Cai; Xiangmei Chen; Javier Zamora; Giovanni A Giuliano; Norbert Braun; Annalisa Perna
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-28       Impact factor: 8.237

Review 4.  Membranous nephropathy: from models to man.

Authors:  Laurence H Beck; David J Salant
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 5.  Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms.

Authors:  Corrado Murtas; Gian Marco Ghiggeri
Journal:  J Nephrol       Date:  2016-01-25       Impact factor: 3.902

Review 6.  Membranous nephropathy: not just a disease for adults.

Authors:  Rivka Ayalon; Laurence H Beck
Journal:  Pediatr Nephrol       Date:  2013-12-29       Impact factor: 3.714

7.  ACTH (Acthar Gel) Reduces Toxic SOD1 Protein Linked to Amyotrophic Lateral Sclerosis in Transgenic Mice: A Novel Observation.

Authors:  Hasan Arrat; Thomas J Lukas; Teepu Siddique
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

Review 8.  The Influence and Role of Microbial Factors in Autoimmune Kidney Diseases: A Systematic Review.

Authors:  Andreas Kronbichler; Julia Kerschbaum; Gert Mayer
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

9.  Role of anti-phospholipase A(2) receptor antibodies in the differential diagnosis of diabetic and membranous nephropathy.

Authors:  Mirjam Pocivalnik; Oleksiy Tsybrovskyy; Christoph Schwarz; Alexander R Rosenkranz; Kathrin Eller; Philipp Eller
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

10.  The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4.

Authors:  Lei Peng; Jing Ma; Rui Cui; Xiao Chen; Shi-Yao Wei; Qiu-Ju Wei; Bing Li
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.